Surgery Alone or With Bladder Chemotherapy for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer
Compares bladder tumor removal alone with added mitomycin treatment in adults with bladder cancer.
Key facts
- Who runs it
- Chinese University of Hong Kong
- Where
- Hong Kong and Shatin, Hong KongSee the 2 sites
- Trial code
- Registry title
- The Role of ERBT Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk NMIBC
- Status
- Not yet recruiting
- People taking part
- 440 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 31 Mar 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ERBT and Adjuvant MMC Therapy
- ERBT
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with intermediate-risk non-muscle-invasive bladder cancer whose tumour was removed in one piece (ERBT) with clear margins and who cannot or will not have intravesical BCG therapy.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Intermediate-risk non-muscle-invasive bladder cancer (NMIBC), confirmed by tissue examination.
- Earlier treatment
- ERBT (en bloc resection of bladder tumour) must have been done successfully with clear resection margins. People cannot join if they had earlier chemotherapy or BCG instilled into the bladder.
Main reasons for not taking part
- Any earlier chemotherapy instillations into the bladder
- Any earlier intravesical BCG therapy
- Current or past cancer of the upper urinary tract
- Serious heart disease or severe chronic lung disease (COPD GOLD Stage III or IV)
- ECOG performance status 2 or higher, pregnancy, or another active cancer
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age ≥ 18 years old with informed consent
- ERBT was successfully performed with clear resection margins
- Histologically confirmed intermediate-risk NMIBC
- Patients who are ineligible or refused to undergo intravesical BCG therapy
Who cannot take part
- Any prior use of intravesical induction and/or maintenance chemotherapy instillations
- Any prior use of intravesical BCG therapy
- Presence or prior history of upper urinary tract malignancy
- Presence of clinically significant cardiovascular disease (History of acute myocardial infarction, presence of uncontrolled angina within 3 months before screening, New York Heart Association Class III or IV congestive heart failure, presence of ventricular arrhythmias, or presence of second-degree or third-degree heart block) (20)
- Presence of GOLD Stage III or IV chronic obstructive pulmonary disease (21)
- Presence of other active malignancy
- ECOG performance status ≥ 2 (Ambulatory and capable of all self-care but unable to carry our any work activities)
- Pregnancy
Where in Hong Kong
- Prince of Wales HospitalHong Kong, Hong KongContact: Yuen Chun Jeremy O TEOH, MDNot yet recruiting
- Prince of Wales HospitalShatin, Hong KongContact: Yuen Chun Jeremy O TEOH, MDNot yet recruiting
About the trial
What the trial wants to find out
This is a prospective, multi-centre randomised trial comparing between ERBT plus 1-year of Ad-MMC, versus ERBT alone, in treating intermediate-risk NMIBC.
The 2 groups in the trial
- ERBT and Ad-MMC groupTreatment being tested
Subject will receive induction course of intravesical mitomycin C within 4 weeks after ERBT. The induction course consists of six weekly doses (+/-2 days) of intravesical mitomycin C (40mg mitomycin C). Afterwards, patients will receive ten monthly (+/-7 days) doses of intravesical mitomycin C (40mg mitomycin C) up to one year as maintenance course. The whole induction and maintenance course of Ad-MMC lasts for about one year
Treatment: ERBT and Adjuvant MMC Therapy
- ERBT GroupExisting treatment, for comparison
No Adjuvant treatment
Treatment: ERBT
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomised Trial Investigating The Role of En Bloc Resection of Bladder Tumour Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer
- Plain-language title
- Surgery Alone or With Bladder Chemotherapy for Intermediate-Risk Non-Muscle-Invasive Bladder CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 30 October 2026